Posted by Administrator on January 19th, 2006 — in Clarinex News
KENILWORTH, N.J., Nov. 8 /PRNewswire/ — More than 80 percent of people with allergic rhinitis experience symptoms in the morning and approximately half indicate symptoms are most severe in the morning, particularly when they first awake, according to a national survey presented at the American College of Allergy, Asthma and Immunology (ACAAI) Annual Scientific Meeting […]
No Comments »
Posted by Administrator on January 19th, 2006 — in Clarinex News
The Food and Drug Administration cleared a reformulated version of Schering-Plough’s (SGP:NYSE - news - research) orally disintegrating Clarinex Reditabs.
The tablets can be taken once daily by adults and kids 6 years and older, the Kenilworth, N.J., company said Friday. The allergy medicine is available in two dosages, 2.5 milligrams and 5 milligrams of […]
No Comments »
Posted by Administrator on January 11th, 2006 — in Clarinex News
KENILWORTH, N.J., March 4 — Schering-Plough Corporation ( NYSE = SGP ) today announced that the U.S. Food and Drug Administration (FDA) has approved CLARINEX-D(R) 24 HOUR (desloratadine 5mg and pseudoephedrine sulfate USP 240 mg) Extended Release Tablets for the relief of the nasal and non-nasal symptoms of seasonal allergic rhinitis (outdoor allergies), including nasal […]
No Comments »
Posted by Administrator on January 11th, 2006 — in Clarinex News
EDEN PRAIRIE, Minn., Aug. 25 — CIMA LABS INC., a Cephalon company ( NASDAQ = CEPH ) , announced today that Schering-Plough Corporation plans to market an orally disintegrating version of CLARINEX(R) (desloratadine), its prescription antihistamine product using OraSolv(R), a proprietary orally disintegrating drug delivery technology developed by CIMA LABS.
Schering-Plough announced in July that […]
No Comments »